Aviv Biomedical Awarded a Phase II SBIR

Aviv Biomedical Inc. has been awarded a Phase II Small Business Innovation Research Grant (SBIR) for a Point of Care System for Determination of Bilirubin Binding Capacity in Neonates. Public Health Relevance: Kernicterus is a preventable brain injury in neonates; it is re-emerging in the USA.1 Present day methods of…

Continue reading